PARP1 inhibition by Olaparib, compared to the control, substantially reduced the tumor size and tumor load, albeit had no statistically significant impact on tumor number was observed in the tumor-laden Apcmin716/+ mice (Figure 7E). This evidence concerns the gene PARP1 and neoplasm.